search
Search
Kingdom of Norway contributes NOK 600 million to IFFIm
New donation will back Vaccine Bonds to fund CEPI’s fight against deadly diseases Geneva, 29 May 2019 – The Kingdom of Norway has agreed to donate NOK 600 million to the International Finance Facility for Immunisation (IFFIm). The donation is…
Norway increases and prolongs support for global immunisation until 2015
Norway Joins the International Finance Facility for Immunization (IFFIm) New Delhi, 7 December 2005 - The Prime Minister of Norway, Jens Stoltenberg, announced today that starting in 2006 the Government of Norway will boost its annual support to…
Norway contributes NOK 2 billion to IFFIm
The pledge will back Vaccine Bonds, funding CEPI’s COVID-19 programme London, 12 June 2020 – The Kingdom of Norway has committed NOK 2 billion (approximately US$ 200 million) to the International Finance Facility for Immunisation (IFFIm) to…
IFFIm Returns to Market with US$ 750 Million 5-year Oversubscribed Vaccine Bonds
The issuance, IFFIm’s largest since 2006, will raise funding for Gavi’s core immunisation programmes and the Gavi COVAX Advance Market Commitment (AMC). The Vaccine Bonds are backed by pledges from 10 sovereign donors, including recent new…
Norway Renews its Support for IFFIm with US$421 Million Pledge
The 10-year commitment to support Gavi vaccine programmes is part of Norway’s US$ 1 billion commitment to Gavi London, 8 May 2020 – Norway has committed an additional US$ 412 million over the next 10 years to the International Finance Facility…
World Leaders Pledge US$ 926 Million to IFFIm
Italy, the Netherlands, Norway and Spain have affirmed their continued support of IFFIm, together contributing a total of US$ 926 million in new, long-term funding to International Finance Facility for Immunisation (IFFIm). The pledges were made in…
IFFIm rating action by Fitch follows France downgrade
Fitch Ratings has downgrades the long-term credit rating of the International Finance Facility for Immunisation (IFFIm) from AA+ to AA with a stable outlook. Washington DC, 17 December 2014 — Fitch Ratings has downgraded the long-term credit rating…
IFFIm issues NOK 2 billion in Vaccine Bonds for COVID-19 vaccine development
IFFIm has issued NOK 2 billion in Vaccine Bonds to accelerate the availability of financing for urgent COVID-19 vaccine research and development by the Coalition for Epidemic Preparedness Innovations London, 7 July 2020 – The International Finance…
Japanese investors offered new opportunity to purchase life-saving vaccine bonds
This is the third vaccine bond issue that HSBC has arranged following successful issues in 2009 and 2010 that raised a total of USD 300 million. Investors will be offered a 3-year fixed-rate South African rand-denominated bond, a 4.5-year fixed-…
Key European Nations join UK and France to commit nearly US$4 billion to expand child immunisation in developing countries
Innovative financing approach will tap capital markets to maximize impact of funds London, 9 September - The United Kingdom, France, Italy, Spain, and Sweden today committed nearly US$4 billion to support and scale up the work of the Global…
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.